TGFBR1 and colorectal neoplasm: We tested this therapeutic strategy using a clinically relevant small molecule inhibitor of ALK5, LY2157299 (LY, a.k.a. Galunisertib), administered prior to chemo-radiation in mice bearing established colorectal tumors.